In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on VistaGen Therapeutics (NASDAQ: VTGN), with a price target of $6. The company’s shares opened today at $1.26.
Palomeque commented:
“Over the weekend, CNN picked up a story on the use of Ketamine (blocks NMDA receptor) for the off-label treatment for major depressive disorder (MDD), highlighting a patient with treatment resistant depression (TRD) and suicidal-ideation experiencing symptom relief for the first time in his adult life (VIDEO LINK), (ARTICLE LINK). This is a significant positive for the NMDA-targeting space, including VistaGen. We also highlight a recent paper published in July on Ketamine use in kids with TRD.”
According to TipRanks.com, Palomeque is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.0% and a 33.3% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, Anavex Life Sciences, and Neurotrope.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for VistaGen Therapeutics with a $11.33 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.65 and a one-year low of $0.69. Currently, VistaGen Therapeutics has an average volume of 843.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
